The pharmaceutical company Mark issued a statement: “We will seek FDA approval for the use of the drug we developed against Corona.” The drug trial was discontinued in advanced stages, after indicating significant efficacy in reducing the risk of hospitalization or coronary heart disease by half.
If the U.S. Food and Drug Administration approves the drug, called Molnofiravir, it will be the first treatment given in pills, on a twice-daily prescription for five days – for Corona patients.
According to the company, an intermediate analysis of the results of the experiment showed that 7.3% of the patients treated with the drug died or were hospitalized – compared to 14.1% of the placebo recipients.
The decision to stop the study was made following a recommendation by an independent committee of scientists monitoring the experiment, and after consultations with the FDA.
The Merck company said that “an intermediate analysis of data from 775 patients showed that none of the participants who received Molnofiravir – died during the first 29 days of the study, compared to eight who received a placebo.”
Meanwhile, the company said it would submit a permit for emergency use of the drug in the U.S. in the next two weeks. At the same time, it would seek green light in several other countries. The current corona. “